GlycoMimetics (GLYC) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
GlycoMimetics Reports Third Quarter 2018 Results and Highlights Recent Company Achievements
November 2, 2018 7:30 AM EDTContinued to select new clinical sites and ready previously-selected sites in the U.S., Europe, Canada and Australia for the company-sponsored Phase 3 pivotal trial in relapsed/refractory AML; study now open for enrollment Received notice of Japanese patent issuance in August for uproleselan (GMI-1271) composition of matter as well as pharmaceutical formulations, expiring in December 2032 On November 1, announced that six abstracts have been accepted for oral and poster presentations at the Annual Meeting of the American Society of Hematology (ASH) in December... More
